We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
+31.45%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$854M
AUM Growth
+$40.2M
Cap. Flow
-$21.9M
Cap. Flow %
-2.56%
Top 10 Hldgs %
56.07%
Holding
53
New
14
Increased
5
Reduced
13
Closed
13

Top Buys

Rank Stock Value
1
IMVT icon
Immunovant
IMVT
+$39.7M
2
XENE icon
Xenon Pharmaceuticals
XENE
+$14.6M
3
RCKT icon
Rocket Pharmaceuticals
RCKT
+$13.8M
4
COGT icon
Cogent Biosciences
COGT
+$13.6M
5
ATXS
Astria Therapeutics
ATXS
+$8.92M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$25.8M
2
VTYX
Ventyx Biosciences
VTYX
+$21.9M
3
BCYC
Bicycle Therapeutics
BCYC
+$15.2M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$15.1M
5
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$13.9M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IDYA icon
1
IDEAYA Biosciences
IDYA
$3.5B
$70.9M 8.3%
3,900,000
-235,000
-6% -$3.95M
APLS
2
DELISTED
Apellis Pharmaceuticals
APLS
$69.8M 8.18%
1,350,000
+50,000
+4% +$2.65M
CYTK icon
3
Cytokinetics
CYTK
$10.9B
$68.7M 8.05%
1,500,000
-200,000
-12% -$8.61M
IMVT icon
4
Immunovant
IMVT
$8.27B
$55.9M 6.55%
+3,150,000
New +$39.7M
ALLK
5
DELISTED
Allakos
ALLK
$44.5M 5.21%
5,286,666
-650,000
-11% -$4.52M
BCYC
6
Bicycle Therapeutics
BCYC
$275M
$42.5M 4.98%
1,435,000
-565,000
-28% -$15.2M
XENE icon
7
Xenon Pharmaceuticals
XENE
$6.36B
$35.5M 4.16%
900,000
+400,000
+80% +$14.6M
ISEE
8
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$32.1M 3.76%
1,500,000
– –
KRTX
9
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$29.5M 3.45%
150,000
– –
VRDN icon
10
Viridian Therapeutics
VRDN
$2.18B
$29.2M 3.42%
1,000,000
– –
DSGN icon
11
Design Therapeutics
DSGN
$748M
$28.7M 3.36%
2,797,501
– –
IMCR icon
12
Immunocore
IMCR
$1.78B
$28.5M 3.34%
500,000
+150,000
+43% +$8.44M
SRPT icon
13
Sarepta Therapeutics
SRPT
$1.7B
$28.5M 3.34%
220,000
-130,000
-37% -$15.1M
ALXO icon
14
ALX Oncology
ALXO
$280M
$26.5M 3.1%
2,349,600
-621,752
-21% -$6.98M
DYN icon
15
Dyne Therapeutics
DYN
$4.2B
$24.9M 2.92%
2,150,000
-137,321
-6% -$1.59M
AKRO
16
DELISTED
Akero Therapeutics
AKRO
$21.9M 2.57%
400,000
– –
VTYX
17
DELISTED
Ventyx Biosciences
VTYX
$21.5M 2.52%
657,016
-740,664
-53% -$21.9M
ARQT icon
18
Arcutis Biotherapeutics
ARQT
$3.55B
$20.7M 2.43%
1,400,000
-125,000
-8% -$2.18M
DICE
19
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$20.6M 2.41%
660,000
-425,251
-39% -$13.9M
MDGL icon
20
Madrigal Pharmaceuticals
MDGL
$12.9B
$17.4M 2.04%
+60,000
New +$5.87M
RCKT icon
21
Rocket Pharmaceuticals
RCKT
$357M
$14.7M 1.72%
+750,000
New +$13.8M
FULC icon
22
Fulcrum Therapeutics
FULC
$251M
$14.6M 1.71%
2,000,000
+50,000
+3% +$326K
ATXS
23
DELISTED
Astria Therapeutics
ATXS
$12.9M 1.51%
+864,960
New +$8.92M
COGT icon
24
Cogent Biosciences
COGT
$6.95B
$12.7M 1.49%
+1,100,000
New +$13.6M
GERN icon
25
Geron
GERN
$962M
$9.68M 1.13%
4,000,000
+2,000,000
+100% +$4.48M
1
2 3

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q4 2022 Portfolio in Review

As of Q4 2022, Logos Global Management held 53 positions worth $854M, up 4.9% from $813M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Logos Global Management's Q4 2022 filing shows 14 new, 5 increased, 13 reduced and 13 closed positions. Its largest new stake was Immunovant: 3,150,000 shares worth $55.9M. The largest sale was Ascendis Pharma A/S, an estimated $25.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

  • Logos Global Management's largest Q4 2022 buy was Immunovant: 3,150,000 shares worth $55.9M.
  • Logos Global Management added most to Xenon Pharmaceuticals in Q4 2022, an estimated $14.6M increase.
  • Logos Global Management's biggest Q4 2022 reduction was Ventyx Biosciences, cutting an estimated $21.9M.
  • Logos Global Management fully exited Ascendis Pharma A/S in Q4 2022, selling an estimated $25.8M.
  • Logos Global Management's ten largest holdings make up 56% of its $854M portfolio in Q4 2022.
  • Logos Global Management opened 14 new positions and closed 13 in Q4 2022.
  • Logos Global Management's portfolio value rose 4.9% quarter-over-quarter to $854M.

Based on Logos Global Management's 13F filing for Q4 2022, filed 14 Feb 2023.